BioMosaics

GPC3 (Human Glypican-3) Immunoassay Catalog # B1507

The GPC3 Immunoassay is a sandwich-ELISA for the determination of human Glypican-3 protein concentrations in cell culture supernatants, cell lysates and human serum. The assay employs two GPC3-specific monoclonal antibodies; one is immobilized to the surface of microtiter wells provided with the kit. Samples or GPC3 standards are incubated for 2 hours, followed by a second 2 hour incubation with the secondary detector antibody. Total time for the assay, including setup, wash and data collection, is approximately 6 hours.

Glypicans are a family of heparan sulfate proteoglycans that are linked to the exocytoplasmic surface of cell membranes by a glycosyl phosphatidylinositol (GPI) anchor. Glypican-3 is an oncofetal antigen that has been found to be mutated in Simpson-Golabi-Behmel syndrome (SGBS). This X-linked disorder is characterized by overgrowth and a broad spectrum of clinical manifestations. In addition to its upregulation in certain cancers, GPC3 is downregulated in breast cancer, ovarian cancer and mesothelioma. It is capable of activating the non-canonical Wnt pathway, and downregulation appears to be mediated by promoter methylation. It is a useful immunohistochemical marker of early hepatocellular carcinoma. It has been implicated in other types of cancer, including squamous cell carcinoma of the lung, melanoma and testicular germ cell tumors.